Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial

Type 1 diabetes remains an important health-care problem, with no disease-modifying therapies available in people with recent-onset, clinical type 1 diabetes. Adaptive trial designs, allowing faster evaluation of treatment modalities, remain underexplored in this stage of the disease. We aimed to id...

Full description

Bibliographic Details

Published in:	The Lancet (British edition) Vol. 406; no. 10510; p. 1375
Main Authors:	Mathieu, Chantal, Wych, Julie, Hendriks, A Emile J, Van Ryckeghem, Lisa, Tree, Timothy, Chmura, Piotr, Möller, Christopher, Casteels, Kristina, Danne, Thomas, Reschke, Felix, Šmigoc Schweiger, Darja, Battelino, Tadej, Johannesen, Jesper, Rami-Merhar, Birgit, Pieber, Thomas, De Block, Christophe, Evans, Mark, Hilbrands, Robert, Bosi, Emanuele, Willemsen, Ruben H, Basu, Supriyo, Pulkkinen, Mari-Anne, Knip, Mikael, Cnop, Miriam, Nitsche, Almut, Schulte, Anke M, Niemöller, Elisabeth, Peakman, Mark, Wilhelm-Benartzi, Charlotte, Gillespie, David, Overbergh, Lut, Mander, Adrian P, Marcovecchio, M Loredana
Format:	Journal Article
Language:	English
Published:	England 27.09.2025
Subjects:	Adolescent Adult Antilymphocyte Serum - administration & dosage Antilymphocyte Serum - adverse effects Child Child, Preschool Diabetes Mellitus, Type 1 - drug therapy Dose-Response Relationship, Drug Double-Blind Method Female Humans Immunosuppressive Agents - administration & dosage Male Treatment Outcome Young Adult
ISSN:	1474-547X, 1474-547X
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!